Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Partners Demonstration Project: PrEP and ART for HIV Prevention
NCT02775929Phase 4Completed
- Sponsor
- University of Washington
- Start
- Nov 2012
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by University of Washington. Primary endpoint: Ability to recruit high-risk HIV-1 serodiscordant couples: Screen-to-eligible ratio at 24 months. Started Nov 2012; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02775929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02775929.